{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:48:34Z","timestamp":1761540514230},"reference-count":15,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,3,22]],"date-time":"2004-03-22T00:00:00Z","timestamp":1079913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To assess the safety of a highly purified, plasma\u2010derived factor VIII concentrate (Replenate\u00ae) in routine clinical use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Following guidelines entitled safety assessment of marketed medicines (SAMM), safety data were collected in the UK on 194 patients who received an estimated 47.6 million IU of Replenate\u00ae. This population included 47 patients undergoing 53 surgical operations or dental extractions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study detected four cases of new factor VIII inhibitor development and twelve other adverse events, five that were unrelated to the product, five whose causality was unknown, one that was possibly product\u2010related and one case due to possible lack of efficacy. Only one of these cases had been notified to the manufacturer through conventional spontaneous reporting procedures. Three patients were switched from Replenate\u00ae as a result of an adverse event (one case of infusion site irritation and two cases of a rise in titre of an existing inhibitor), but no unexpected adverse reactions were noted and there were no reports of virus transmission. The median factor VIII recovery value was 2.17 IU\/dl per IU\/kg, but recovery was shown to be dependent on several variables, namely inhibitor status, treatment centre and the patient's body weight. The median factor VIII recovery in inhibitor\u2010free patients was 2.28 IU\/dl per IU\/kg (range: 1.20\u20136.62).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The study confirms that Replenate\u00ae is well tolerated by the majority of patients in routine clinical practice. \u00a9 Crown copyright 2004. Reproduced with the permission of Her Majesty's Stationery Office. Published by John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.956","type":"journal-article","created":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T08:01:24Z","timestamp":1080806484000},"page":"243-252","source":"Crossref","is-referenced-by-count":3,"title":["A retrospective survey on the safety of Replenate\u00ae, a high\u2010purity factor VIII concentrate"],"prefix":"10.1002","volume":"13","author":[{"given":"E. W.","family":"Gascoigne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. H.","family":"Dash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Harman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Wilmot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,3,22]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91955-8"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90044-H"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1655911"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91483-8"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92393-T"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.911"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1994.tb04329.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0038-1648373","article-title":"Treatment of haemophilia A with a highly purified factor VIII concentrate prepared by anti\u2010FVIIIc immunoaffinity chromatography","volume":"67","author":"Addiego JE","year":"1992","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-199412003-00006"},{"key":"e_1_2_1_11_2","volume-title":"Report on the Annual Returns for 1996","author":"UK Haemophilia Centre Directors Organisation","year":"1998"},{"issue":"1","key":"e_1_2_1_12_2","first-page":"22","article-title":"Assessment of the potency of factor VIII concentrates","volume":"2","author":"Snape TJ","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_1_13_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1055\/s-0038-1646292","article-title":"Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M)","volume":"68","author":"Morrfini M","year":"1992","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1055\/s-0038-1646492","article-title":"In vivo recovery and survival of monoclonal\u2010antibody\u2010purified factor VIII concentrates","volume":"66","author":"Kasper CK","year":"1991","journal-title":"Thromb Haemost"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.440641.x"},{"issue":"2","key":"e_1_2_1_16_2","first-page":"1","article-title":"Viral safety and inhibitor development associated with factor VIIIc ultra\u2010purified from plasma in hemophiliacs previously unexposed to factor VIIIc concentrates","volume":"27","author":"Lusher JM","year":"1990","journal-title":"Sem Hematol"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.956","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T23:30:04Z","timestamp":1696635004000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3,22]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1002\/pds.956"],"URL":"https:\/\/doi.org\/10.1002\/pds.956","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,3,22]]}}}